Paper · 2026 · Open access

Artificial Intelligence in Drug Development

Shruti Patil*, Srushti Devkule, Vaishnavi Mane, Lija Mujawar

Zenodo (CERN European Organization for Nuclear Research) · Published 14 June 2026 · DOI 10.5281/zenodo.20689843

Read the free full textCite this paper

In brief

“Artificial Intelligence in Drug Development” is a 2026 paper by Shruti Patil*, Srushti Devkule, Vaishnavi Mane, Lija Mujawar, published in Zenodo (CERN European Organization for Nuclear Research). OpenAlex counts 0 citations as of 15 November 2026. It is open access under a CC BY licence: the full text is free to read at Zenodo (CERN European Organization for Nuclear Research).

Citations
0
Authors
1

Abstract

Artificial Intelligence(AI) has emerged as a revolutionary in drug development, significantly transforming traditional pharmaceutical research processes. Conventional drug discovery is time consuming, costly and associated with high failure rates, often requiring more than a decade for successful drug approval. AI technologies such as Machine Learning(ML), Deep Learning(DL) and Natural Language Processing(NLP) provide advanced computational tools that accelerates drug discovery, improve prediction accuracy and enhance decision making throughout the development pipeline. AI application include target identification, biomarker discovery, drug design, toxicity prediction, drug purposing and optimization of clinical trials. In preclinical studies, AI assists in predicting toxicity, analyzing biomedical data and improving pharmacokinetic and pharmacodynamic modeling. During clinical trials, AI supports patient selection, adherence monitoring, endpoint detection and trial optimization, thereby reducing time and cost.AI also enables personalized medicine through the analysis of genomics, proteomics and clinical data. Despite its numerous advantages, challenges such as data privacy, lack of standardized regulations, interpretability of AI models and shortage of skilled professionals remain significant barrier to implementation. Neverthless, ongoing advancements in AI and increasing integration of healthcare data are expected to further enhance pharmaceutical research and healthcare outcomes. Overall, AI has the potential to revolutionize drug development by improving efficiency, reducing costs and increasing the success rate of discovering safe and effective medicines.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Mujawar, S. P. S. D. V. M. L. (2026). Artificial Intelligence in Drug Development. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.20689843

MLA 9

Mujawar, Shruti Patil*, Srushti Devkule, Vaishnavi Mane, Lija. “Artificial Intelligence in Drug Development.” Zenodo (CERN European Organization for Nuclear Research), 2026. https://doi.org/10.5281/zenodo.20689843.

Chicago

Mujawar, Shruti Patil*, Srushti Devkule, Vaishnavi Mane, Lija. 2026. “Artificial Intelligence in Drug Development.” Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.20689843.

Harvard

Mujawar, S. P. S. D. V. M. L. (2026) ‘Artificial Intelligence in Drug Development’, Zenodo (CERN European Organization for Nuclear Research). doi:10.5281/zenodo.20689843.

IEEE

S. P. S. D. V. M. L. Mujawar, “Artificial Intelligence in Drug Development,” Zenodo (CERN European Organization for Nuclear Research), 2026, doi: 10.5281/zenodo.20689843.

BibTeX

@article{mujawar2026artificial,
  title     = {{Artificial Intelligence in Drug Development}},
  author    = {Mujawar, Shruti Patil*, Srushti Devkule, Vaishnavi Mane, Lija},
  journal   = {Zenodo (CERN European Organization for Nuclear Research)},
  year      = {2026},
  doi       = {10.5281/zenodo.20689843},
  url       = {https://doi.org/10.5281/zenodo.20689843}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • artificial intelligence in drug development
  • drug discovery
  • machine learning
  • deep learning
  • natural language processing
  • target identification
  • biomarker discovery
  • drug design

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Mujawar, S. P. S. D. V. M. L. (2026). Artificial Intelligence in Drug Development. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.20689843

How many times has this paper been cited?

0 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Zenodo (CERN European Organization for Nuclear Research).

Who wrote this paper?

Shruti Patil*, Srushti Devkule, Vaishnavi Mane, Lija Mujawar.

What is the DOI of this paper?

10.5281/zenodo.20689843. The permanent link is https://doi.org/10.5281/zenodo.20689843.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.